Flowchart of trial.
Mean aerobic capacity and exercise tolerance for each treatment group, adjusting for pretreatment levels of depression. Compared with patients in the medication group, those in the exercise and combination groups showed significantly higher aerobic capacity (V̇O2) (left) and longer treadmill test duration (right) after 16 weeks of treatment. Error bars represent SEs.
Observed mean depression scores before and after treatment. All changes from pretreatment to posttreatment were statistically significant (P<.001 for all). The treatment groups did not differ on baseline or posttreatment levels of depression. Error bars represent SEs. HAM-D indicates Hamilton Rating Scale for Depression; BDI, Beck Depression Inventory.
Fitted values for Hamilton Rating Scale for Depression (HAM-D) (left) and Beck Depression Inventory (BDI) (right) across 16 weeks of treatment. Values represent the fitted scores in each treatment group for 2 selected values of baseline depression treatment (22 for moderate to severe and 16 for mild). Week 0 values represent the baseline starting points selected for this illustration and were not generated by the model. Depression ratings of mild and moderate to severe are at baseline.
Blumenthal JA, Babyak MA, Moore KA, Craighead WE, Herman S, Khatri P, Waugh R, Napolitano MA, Forman LM, Appelbaum M, Doraiswamy PM, Krishnan KR. Effects of Exercise Training on Older Patients With Major Depression. Arch Intern Med. 1999;159(19):2349–2356. doi:10.1001/archinte.159.19.2349
Previous observational and interventional studies have suggested that regular physical exercise may be associated with reduced symptoms of depression. However, the extent to which exercise training may reduce depressive symptoms in older patients with major depressive disorder (MDD) has not been systematically evaluated.
To assess the effectiveness of an aerobic exercise program compared with standard medication (ie, antidepressants) for treatment of MDD in older patients, we conducted a 16-week randomized controlled trial.
One hundred fifty-six men and women with MDD (age, ≥50 years) were assigned randomly to a program of aerobic exercise, antidepressants (sertraline hydrochloride), or combined exercise and medication. Subjects underwent comprehensive evaluations of depression, including the presence and severity of MDD using Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and Hamilton Rating Scale for Depression (HAM-D) and Beck Depression Inventory (BDI) scores before and after treatment. Secondary outcome measures included aerobic capacity, life satisfaction, self-esteem, anxiety, and dysfunctional cognitions.
After 16 weeks of treatment, the groups did not differ statistically on HAM-D or BDI scores (P = .67); adjustment for baseline levels of depression yielded an essentially identical result. Growth curve models revealed that all groups exhibited statistically and clinically significant reductions on HAM-D and BDI scores. However, patients receiving medication alone exhibited the fastest initial response; among patients receiving combination therapy, those with less severe depressive symptoms initially showed a more rapid response than those with initially more severe depressive symptoms.
An exercise training program may be considered an alternative to antidepressants for treatment of depression in older persons. Although antidepressants may facilitate a more rapid initial therapeutic response than exercise, after 16 weeks of treatment exercise was equally effective in reducing depression among patients with MDD.
AGING OF THE population and the increased prevalence of chronic diseases among the elderly are major challenges facing our society and medical community. Depression is a significant cause—and consequence—of disability among older individuals. Estimates of the prevalence of mood disorders in the United States range from approximately 5% to 10% of elderly community dwellers1,2 to 18% of nursing home residents.3 Depressive symptoms are associated with the presence of 1 or more chronic diseases4,5 as well as disability,2 including days in bed and days away from normal activities.5 Moreover, major depressive disorder (MDD) has been associated with a 59% increase in mortality risk during a 1-year follow-up.3
The most frequently used treatment for major depression is antidepressant medication.6 Despite the development of new and effective medications for depression, as many as 30% to 35% of patients do not respond to treatment.7- 9 Furthermore, medications also may induce unwanted side effects that can impair patients' quality of life and reduce compliance.9 Even among patients who show improvement with short-term antidepressant use, there is a significant risk for relapse within 1 year following treatment termination.10- 12
The potential use of aerobic exercise as an alternative or complementary treatment for depression has received considerable attention recently.13 Anecdotal reports, followed by observational and interventional studies of young and middle-aged adults, suggest that aerobic exercise is superior to placebo or to no treatment14- 16 and is better than or equal to other treatments, including psychotherapy17- 19 or occupational therapy,20 in reducing depressive symptoms. These studies have been plagued by methodological problems, however, including limited sample sizes, lack of randomized designs, uncontrolled concurrent therapies, failure to document exercise training effects, and imprecise diagnosis of depression. To date, only a single study has examined the effects of exercise as a treatment for depression in a group of 30 older adults.21 Although patients reported a significant reduction in depressive symptoms measured by the Beck Depression Inventory (BDI) compared with wait-list controls (subjects on a waiting list for treatment who served as controls), the study had important limitations, including a small sample size, imprecise diagnosis of depression, brief (ie, 6-week) treatment period, lack of a standardized exercise regimen, and failure to document exercise training.
Other studies of the effects of exercise training on older, healthy, nondepressed adults suggest a number of potential psychological benefits, including improvements in cognitive function, mood, and sense of well-being.22- 27 A previous study in our laboratory found lower levels of depressive symptoms among older men following 4 months of exercise training.28 Other studies of older patients with medical conditions also have shown improvements of psychosocial functioning as a consequence of exercise training.29- 33 Although these studies are suggestive, to our knowledge the therapeutic effects of exercise on clinical depression have not been evaluated systematically.
Our study accomplishes this goal through a comparison of exercise treatment with the current standard intervention—antidepressant medication—in a group of older adults with MDD. We addressed the following specific questions: (1) How do the therapeutic effects of group exercise training compare with those of antidepressant (sertraline hydrochloride [Zoloft]) therapy? (2) Is there added benefit from combining both treatment modalities? (3) Do patients with different severity levels of depressive symptoms respond differentially to the respective treatment approaches? and (4) How do the treatments compare with respect to the rate of change of depressive symptoms?
Subjects were recruited through flyers, media advertisements, and letters sent to local physicians and mental health facilities. Respondents who appeared to meet the study inclusion criteria attended an initial screening interview with a trained clinical psychologist (W.E.C., S.H.) who determined the presence and severity of MDD using relevant parts of the Diagnostic Interview Schedule34 and the 17-item Hamilton Rating Scale for Depression (HAM-D).35 Subjects were considered eligible for the study if they met criteria of the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition (DSM-IV)36 for MDD (depressed mood or loss of interest or pleasure, and at least 4 of the following symptoms: sleep disturbance, weight loss or change in appetite, psychomotor retardation or agitation, feelings of worthlessness or excessive guilt, impaired cognition or concentration, and recurrent thoughts of death) and received a severity score of at least 13 on the HAM-D.
Exclusion criteria included current antidepressant use, use of other medications that would preclude random assignment to drug or exercise treatment (eg, quinidine, metoprolol), current alcohol or substance abuse, medical contraindications to exercise (eg, significant orthopedic problems or cardiopulmonary disease that would prevent regular aerobic exercise), primary psychiatric diagnosis other than MDD (eg, bipolar disorder, psychosis), evidence of acute suicidal risk, psychotherapy initiated within the past year, and ongoing participation in regular aerobic exercise.
The HAM-D35 is a 17-item clinical rating scale that was used to determine study eligibility and treatment outcome. Patients who received a HAM-D score within the range of 13 through 18 were considered to be mildly clinically depressed, whereas patients who obtained a HAM-D score of more than 18 were considered to be moderately to severely depressed. To evaluate interrater reliability, 10 randomly selected interviews were independently rated by 2 clinicians. The intraclass correlation for both raters was 0.96. Every effort was made to ensure that clinical raters were unaware of patients' treatment group assignment after randomization. Patients were instructed not to reveal which treatment they received at the time of their posttreatment assessments. The clinical psychologists administering the Diagnostic Interview Schedule and HAM-D were not involved in the provision of any of the treatments or in the interim assessments.
The BDI37 is a 21-item self-report questionnaire consisting of symptoms and attitudes relating to depression, including items such as self-dislike, suicidal ideation, insomnia, and sadness. The items are summed with a range of 0 to 63; higher scores indicate greater depression. The BDI has been shown to be a valid and reliable measure of depression severity.37 A meta-analysis of the internal consistency of the BDI estimates yielded a mean coefficient α of .86 for psychiatric patients and a mean correlation of the BDI and the HAM-D of 0.73.38
The following set of secondary self-report measures was administered before and at the end of the 16-week intervention: (1) State-Trait Anxiety Inventory,39 consisting of 20 items designed to assess acute anxiety (eg, "I feel anxious"). Agreement with each statement is rated on a 4-point scale, with 1 indicating not at all to 4, very much so. Higher scores indicate higher levels of anxiety. (2) Rosenberg Self-Esteem Scale,40 a 10-item scale that measures global self-esteem (eg, "I take a positive attitude toward myself"). Agreement with each statement was rated on a 5-point scale, with 4 indicating strongly agree to 0, strongly disagree. The items were summed such that higher numbers indicate higher self-esteem. (3) Life Satisfaction Index,41 a 20-item index that measures overall life satisfaction (eg, "As I grow older, things seem better than I thought they would be"). Agreement with each statement was rated on a 3-point scale, and the items were summed such that higher numbers indicate greater life satisfaction. (4) Dysfunctional Attitudes Scale,42 a 40-item self-report questionnaire designed to assess the irrational beliefs and faulty assumptions about reality hypothesized by Beck to determine emotional disturbance (eg, "If I fail at my work, then I am a failure as a person"). Agreement with each statement was rated on a 7-point scale, so that higher scores reflect less presence of dysfunctional beliefs.
At baseline and at the conclusion of 4 months of treatment, participants underwent a symptom-limited graded exercise treadmill test under continuous electrocardiographic recording. A modified Balke protocol was used43 in which workloads were increased at a rate of 1 metabolic equivalent per minute. Expired air was collected by mouthpiece for quantification of minute ventilation, oxygen consumption, and carbon dioxide production (2900 Metabolic Cart; Sensormedics, Yorba Linda, Calif). Samples were collected at 15-second intervals, and peak values were determined from an average obtained during the last 60 seconds. Patients exercised to exhaustion or to other standard clinical end points (eg, significant chest pain, drop in blood pressure, complex premature ventricular contractions, progressive ST segment depression).
To assess ongoing treatment response, a trained research assistant (P.K. or M.A.N.) administered the HAM-D and the BDI at weeks 1, 2, 3, 4, 6, 8, and 12.
On completion of the baseline assessment, each participant was randomly assigned to 1 of the following 3 treatments: exercise, medication, or a combination of both. A stratified randomization procedure was used to ensure that roughly proportionate numbers of mildly and moderately to severely depressed patients were assigned to each treatment condition. Treatment began within 1 week of the diagnostic interview.
Subjects attended 3 supervised exercise sessions per week for 16 consecutive weeks. Participants were assigned individual training ranges equivalent to 70% to 85% of heart rate reserve44 calculated from the maximum heart rate achieved during the treadmill test. Each aerobic session began with a 10-minute warm-up exercise period followed by 30 minutes of continuous walking or jogging at an intensity that would maintain heart rate within the assigned training range. The exercise session concluded with 5 minutes of cool-down exercises. Heart rates were monitored via radial pulses and were recorded, along with ratings of perceived exertion, 3 times during each exercise session by a trained exercise physiologist.
Patients received sertraline, a selective serotonin reuptake inhibitor. This medication was selected because of its documented efficacy and favorable side effect profile for the elderly.45 Medication management was provided by a staff psychiatrist (L.M.F., P.M.D., or K.R.K.) who met with each patient at study onset and weeks 2, 6, 10, 14, and 16. At these meetings, the psychiatrist evaluated treatment response and side effects and titrated dosage accordingly. Treatment was initiated with 50 mg and titrated until a well-tolerated therapeutic dosage was achieved of up to 200 mg. An effort was made to follow standard, "usual care" guidelines for medication management, with the exception that a change to a different antidepressant was not permitted during the course of the study.
Patients in this group received concurrently the same medication and exercise regimens described above.
The effects of the intervention on end point depression were assessed using a 1-way multivariate analysis of variance, with posttreatment HAM-D and BDI scores serving as the dependent variables. In addition, to maximize power, we conducted separate analyses of covariance (ANCOVA) using each of the posttreatment outcome scores as the dependent variable and the corresponding baseline measure as the covariate. The ANCOVAs also were used to evaluate treatment effects on aerobic fitness and each of the ancillary psychometric measures. In all cases where ANCOVA was used, preliminary analyses were conducted to confirm that the heterogeneity of slopes assumption was not violated. All analyses were conducted using the intent-to-treat principle. If no observation was recorded at the end of treatment, data were carried forward from the last observation to serve as the outcome value.
In addition to baseline and end point assessments, growth curve modeling techniques were used to explore the form of change during the 16 weeks of the treatment protocol. Growth curve analyses were conducted using SAS PROC MIXED.46 (Technical details of the growth curve models are available from the corresponding author.)
One hundred fifty-six patients (aged 50-77 years) met study criteria and were randomized into the study. The primary reasons for patient exclusion were a failure to meet the criteria for MDD, a HAM-D score of less than 13, or a history of bipolar disorder (Figure 1). Of the patients who met final entry criteria, 48 were randomly assigned to the medication condition, 53 to the exercise condition, and 55 to the combined condition. The treatment groups did not differ with respect to age, sex, level of education, marital status, income, ethnic composition, or history of recurrent depression (Table 1).
Thirty-two patients (20.5%) dropped out before completing the entire 16-week protocol. Dropout rates did not vary significantly across treatment conditions (χ22 = 0.63; P = .73);7 patients (14.6%) in the medication condition, 14 (26.4%) in the exercise condition, and 11 (20.0%) in the combined condition did not complete the study. Six patients (2 from each group) dropped out of the study after randomization but before treatment was initiated owing to dissatisfaction with their group assignments, but were included in the data analysis following the intent-to-treat principle. Ten patients dropped out owing to medication adverse effects (eg, agitation, sleep disturbance, and dizziness), including 5 patients in the combination group and 5 in the medication group. Four additional patients dropped out from the combination group because of difficulties attending the exercise classes (1 patient) or dissatisfaction with the exercise program (3 patients). Twelve patients in the exercise group were unable to complete the program because of logistical difficulties in attending the classes (8 patients) or dissatisfaction with the exercise program (4 patients). Of the 32 patients who dropped out of the study, 7 agreed to complete a depression assessment and treadmill test at the time that they dropped out of the study; these data served as their outcome measures. Study dropouts did not differ from patents who completed the study on baseline HAM-D severity (P = .22), sex (P = .93), marital status (P = .42), race (P = .66), or age (P = .99), although patients who dropped out tended to have higher BDI scores at baseline (P = .09). Seven patients (4 in the combination group and 3 in the exercise group) sustained a musculoskeletal injury during their exercise training that necessitated their use of cycle ergometry as their primary mode of aerobic training.
Adherence to medication treatment was evaluated by pill count; patients appeared to take medications as prescribed (no patient deviated by >5% from the prescribed dosage). The median peak dose of sertraline hydrochloride was 100 mg for the medication and combined treatment groups. Attendance for the 2 exercise conditions also was comparable, with patients in the exercise condition attending a median of 43 sessions (89.6% of scheduled sessions) and patients in the combined condition attending an average of 44 sessions (91.7% of the scheduled sessions). Similarly, the mean percentage of time in target heart rate training range was virtually identical for the exercise (82.4%) and combined (82.4%) groups.
The ANCOVA revealed that the treatment groups differed with respect to improved aerobic capacity (F2,153 = 5.62; P = .004) and treadmill test duration (F2,153 = 7.68; P<.001). Patients in the exercise and combination groups showed significant improvements in aerobic capacity (Figure 2), whereas patients in the medication group did not. Patients in the exercise condition achieved an 11% improvement in aerobic capacity of 2.7 ± 2.8 mL/kg per minute, and patients in the combined condition achieved a 9% improvement in aerobic capacity of 2.3 ± 2.2 mL/kg per minute; patients in the medication condition showed minimal (<3%) improvement. A similar pattern was observed with respect to exercise tolerance, with patients in the exercise group showing a 15% improvement in test duration, those in the combination group showing an 11% improvement, and those in the medication group showing a less than 3% improvement.
All 3 groups exhibited a significant decline in depressive symptoms. Figure 3 displays the mean HAM-D and BDI scores at study entry and at 16 weeks. The treatment groups did not differ significantly on baseline levels of depression as measured by the HAM-D (F2,153 = 0.96; P = .39) or the BDI (F2,153 = 0.90; P = .40). A 1-way multivariate analysis of variance revealed no statistically significant differences among the groups on the HAM-D or the BDI (Wilks λ4,64 = 0.98; P = .67). The ANCOVA models controlling for baseline levels of depression also did not yield any significant treatment effects with respect to the HAM-D (F2,152 = 0.61; P = .55) or BDI (F2,152 = 1.01; P = .37).
Finally, based on DSM-IV criteria for MDD36 and assuming that patients who dropped out of the study were still depressed, the percentage of patients who were no longer classified as clinically depressed at the end of the 4-month treatment period did not differ across treatment groups (χ22 = 0.79; P = .67); 32 patients (60.4%) in the exercise group, 33 (68.8%) in the medication group, and 36 (65.5%) in the combination group no longer met DSM-IV criteria for MDD according to the clinician-rater who was unaware of patients' group status. When the additional criteria of a HAM-D score greater than 6 was added to the DSM-IV classification, the groups again did not differ (χ22 = 1.08; P = .58), with 25 patients (47.2%) in the exercise group, 27 (56.2%) in the medication group, and 26 (47.3%) in the combination group classified as being no longer clinically depressed.
The growth curve analysis for the HAM-D revealed that the rate of treatment response (depression score as a function of time in treatment) differed in a statistically significant manner (P = .02) across the treatment groups depending on the initial severity of depression. This relation can be seen best in the fitted growth curves presented in the left panel of Figure 4, which shows the shape of the change in depression scores at selected values of high and low initial depression. Depressed patients in the medication group exhibited a more rapid initial therapeutic response (within the first few weeks) compared with patients in the other groups. Also, mildly depressed patients appeared to respond more quickly to the combination of medication and exercise than did moderately to severely depressed patients. The trajectory of BDI scores (Figure 4, right) also varied as a function of treatment group and initial severity level of depression such that patients with mild depressive symptoms at baseline who received combination therapy exhibited a more rapid response compared with patients receiving only medication or only exercise. Summaries of the growth curve analyses for the HAM-D and BDI are given in Table 2 and Table 3, respectively.
The groups did not differ at baseline on self-reported levels of anxiety, self-esteem, life satisfaction, or dysfunctional attitudes (Table 4). At 16 weeks, all groups had improved on each of these measures, but these changes were not significantly different across groups.
The results of this study provide empirical support for the notion that a group program of aerobic exercise is a feasible and effective treatment for depression in older adults. Most patients were able to complete the exercise training protocol successfully. Dropout rates and adherence data compare favorably with those reported in other studies of exercise in older populations23,24,26,47 and suggest that the presence of clinical depression does not preclude participation in an exercise program. Moreover, exercising subjects achieved small but clinically and statistically significant improvements in aerobic capacity, which were comparable to changes observed in nonclinical populations of older adults.28
Patients also appeared to achieve significant clinical improvement with exercise training. Among the 156 patients who entered the trial, 60.4% of patients in the exercise condition, 68.8% of patients in the medication condition, and 65.5% of patients in the combined condition no longer met DSM-IV criteria for MDD. All 3 groups also showed significant reductions on HAM-D and BDI scores, indicating that their clinical symptoms were significantly reduced. That exercise was equally effective as medication after 16 weeks of treatment is consistent with findings of other studies of exercise training in younger depressed adults.14,15,17,18 The magnitude of reductions in depression scores is also comparable to the levels achieved using sertraline in other clinical trials of depression.45,48 Moreover, the changes in depressive symptoms found for all treatments in our study are consistent with the extent of improvements reported in more than a dozen studies of psychosocial interventions for MDD.12,49- 53 For example, in the National Institute of Mental Health Collaborative Depression Study,53 36% of patients undergoing cognitive behavior therapy, 43% of patients undergoing interpersonal therapy, and 42% of patients receiving medication (imipramine hydrochloride) were considered "recovered," compared with 47.2% undergoing exercise, 56.2% receiving medication (sertraline), and 47.3% receiving a combination of exercise and medication in our study.
Although patients in all 3 groups achieved comparable improvement by the end of the 16-week treatment program, the rate of response appeared to vary as a function of depression severity. Those patients who received medication alone appeared to have the fastest response to treatment. Patients with less severe depression appeared to respond more quickly to the combination of exercise and medication than their more severely depressed counterparts.
The mechanisms responsible for the reduction in depressive symptoms are unknown. Several observational studies have shown an association between enhanced physical fitness and improved mental health. For example, in a secondary analysis of 4 surveys, positive affect was related directly to the amount of physical activity in household populations of the United States and Canada.54 Data from cross-sectional studies of active and sedentary individuals also suggest an association between physical activity and mood. A number of studies have found that exercise-trained patients obtain significantly lower depression scores on self-report measures than sedentary patients.16,17,21 Data from longitudinal studies, however, have provided mixed results,15,18,19,55 with no clear evidence that improved aerobic capacity is responsible for reduced depression. Data from our study revealed that, among patients who exercised, a small, statistically significant correlation (r = −0.25; P = .02) was found between changes in aerobic capacity and changes in HAM-D scores, suggesting that improved aerobic capacity may have accounted for at least part of the reductions in depression. Other biological mechanisms, including alterations in central norepinephrine activity,56- 58 reduced activity of the hypothalamopituitary-adrenocortical axis,59 and increased secretion of beta endorphins,60 have been suggested as mechanisms by which exercise improves mood, but no data were available to address these possibilities. Psychological mechanisms also may be responsible for the effects of exercise on mood, including increased feelings of self-efficacy, improved self-concept, and reduced dysfunctional or negative thought patterns. Our study offers no definitive conclusions about what psychological processes may mediate the improved mood associated with exercise training.
This was a short-term (16-week) intervention study. The positive changes that were observed among patients treated with exercise also were observed in those receiving medication only. It remains unknown whether differential outcomes might have been obtained with a longer duration of treatment. It also is not clear how resistant the treatment effects will be to relapse over time. Other studies have reported that relapse and long-term recurrence rates for MDD range from 50% to 80%.10,61- 63 Although exercise and antidepressants may be comparable in their short-term effectiveness, there may be important differences in maintenance. Follow-up of these patients is ongoing, and the enduring effects of these interventions will be evaluated subsequently.
Patients also were sufficiently motivated to volunteer for a study of exercise training, tended to be highly educated, and were healthy enough to participate in an exercise program. The extent to which these findings may be generalizable to other older depressed individuals will need to be studied.
Another limitation of our study was the absence of a true no-treatment control group. This prevents us from specifying a "spontaneous recovery" rate against which our treatment results can be compared. After much consideration of this issue during the initial planning of the study, we decided for methodological and ethical reasons to assign patients only to the 3 active treatment groups. Our objective was to compare exercise treatment with an established treatment modality of known effectiveness. The additional value to be gained by including a no-treatment or placebo condition in our study was judged to be minimal compared with the potential negative clinical impact on those study participants assigned to an intervention known to be of lesser effectiveness.64 It has been estimated that approximately 30% of patients respond to placebo65; for example, 21% of patients receiving placebo were considered recovered in the National Institute of Mental Health Treatment of Depression Collaborative Research Program.53 Thus, patients undergoing exercise training in our study achieved approximately 2-fold greater rates of recovery from MDD compared with patients receiving placebo in previous clinical trials. It is therefore unlikely that the benefits of exercise can be attributed solely to placebo effects or spontaneous remission.
Also, because exercise was performed in a group setting, it is possible that the social interaction of study participants may have had a beneficial effect. Future research on exercise may need to control for the level of social involvement by examining the effects of the exercise setting (eg, home vs program-based) on response to treatment. Based on our results, it appears that exercise is associated with clinically significant improvements in depression that are comparable to those of antidepressants for the clinically depressed older adult when performed in a structured and supervised setting.
Accepted for publication March 16, 1999.
Supported by grants MH49679, HL43028, HL49572, and MO1-RR-30 from the National Institutes of Health, Bethesda, Md. Pfizer Pharmaceuticals, New York, NY, provided the medications for this study and financial support (Drs Doraswaimy, Forman, and Krishnan).
We thank Julie Opitek, PhD, Karen Mallow, MA, and Denise DeBruycker, for their assistance in exercise testing and training, and Mohan Chilukuri, MD, for performing the medical screening examination on study participants. The authors also thank the staff at the Duke Center for Living, Durham, NC, for their support of the study.
Reprints: James A. Blumenthal, PhD, Box 3119, Duke University Medical Center, Durham, NC 27710 (e-mail: firstname.lastname@example.org).